{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:05:28Z","timestamp":1771293928498,"version":"3.50.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Public attention has been drawn recently to the commercial availability of noninvasive prenatal screening for rare genetic conditions, despite estimates that the positive predictive value of such tests is low. Many have focused on the importance of educating patients on the difference between screening and diagnostic testing so that they are adequately prepared for the possibility of a false-positive result. Even so, we question whether expanded noninvasive prenatal screening is ready to be used a screening tool. We argue that established public health criteria for evaluating the risks and benefits of a screening tool should be applied to expanded noninvasive prenatal screening. If a test fails to meet accepted standards, governmental agencies should consider regulating the accuracy and promotional claims of commercially available tests.<\/jats:p>","DOI":"10.1097\/aog.0000000000004809","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:01:10Z","timestamp":1654167670000},"page":"1009-1011","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating Expanded Noninvasive Prenatal Screening"],"prefix":"10.1097","volume":"139","author":[{"given":"Michelle J.","family":"Bayefsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur L.","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iffath A.","family":"Hoskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/AOG.0000000000004084","article-title":"Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 226. American College of Obstetricians and Gynecologists","volume":"136","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/gim.2016.97","article-title":"Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics","volume":"18","author":"Gregg","year":"2016","journal-title":"Genet Med"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2471\/BLT.07.050112","article-title":"Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years","volume":"86","author":"Andermann","year":"2008","journal-title":"Bull World Health Organ"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"691.e1","DOI":"10.1016\/j.ajog.2017.10.005","article-title":"Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory","volume":"217","author":"Petersen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pd.5217","article-title":"Clinical experience of laboratory follow-up with noninvasive prenatal testing using cell-free DNA and positive microdeletion results in 349 cases","volume":"38","author":"Schwartz","year":"2018","journal-title":"Prenat Diagn"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/uog.20353","article-title":"Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis","volume":"54","author":"Salomon","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R10-20250423","first-page":"A5359","article-title":"The rate of invasive testing for trisomy 21 is reduced after implementation of NIPT","volume":"64","author":"Bjerregaard","year":"2017","journal-title":"Dan Med J"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/AOG.0000000000004387","article-title":"Privacy risks in prenatal aneuploidy and carrier screening: what obstetricians and their patients need to know","volume":"137","author":"Parobek","year":"2021","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:02:11Z","timestamp":1745434931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004809","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2022-02-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}